(Q42201783)

18 October 2017

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up (English)

1 reference

18 October 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Patrik Nasr

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Per Stål

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Stergios Kechagias

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Mattias Ekstedt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Mats Fredrikson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Rolf Hultcrantz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

23 March 2015

1 reference

18 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

1547-1554

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

3 June 2020

cites work

1 reference

Fatty liver: a novel component of the metabolic syndrome

21 January 2018

1 reference

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

The epidemiology of nonalcoholic fatty liver disease: a global perspective

21 January 2018

1 reference

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

Endpoints and clinical trial design for nonalcoholic steatohepatitis

21 January 2018

1 reference

Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases

21 January 2018

1 reference

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

21 January 2018

1 reference

Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.

21 January 2018

1 reference

Overweight, cardiovascular diseases and diabetes: Health in Sweden: The National Public Health Report 2012. Chapter 7.

21 January 2018

1 reference

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

21 January 2018

1 reference

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels.

21 January 2018

1 reference

Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis

21 January 2018

1 reference

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials?

21 January 2018

1 reference

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

21 January 2018

1 reference

A position statement on NAFLD/NASH based on the EASL 2009 special conference

21 January 2018

1 reference

7 January 2021

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

7 January 2021

Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression

1 reference

7 January 2021

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

1 reference

7 January 2021

The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients

1 reference

7 January 2021

Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy

1 reference

7 January 2021

Final results of a long-term, clinical follow-up in fatty liver patients

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.27368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125077%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference